Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient

被引：4

作者：

Cattaneo, Dario ^{[1
]}

Meraviglia, Paola ^{[2
]}

Cozzi, Valeria ^{[1
]}

Baldelli, Sara ^{[1
]}

Milani, Greta ^{[1
]}

Clementi, Emilio ^{[1
,3
]}

机构：

[1] Univ Milan, Luigi Sacco Univ Hosp, Clin Pharmacol Unit, Milan, Italy

[2] Univ Milan, Luigi Sacco Univ Hosp, Div Infect Dis 2, Milan, Italy

[3] E Medea Sci Inst, Bosisio Parini, Italy

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2012年 / 26卷 / 02期

关键词：

HAART; HIV; pharmacogenetics; pharmacokinetics; therapeutic drug monitoring; PLASMA-CONCENTRATIONS; INFECTED PATIENTS; EFFICACY;

D O I：

10.1111/j.1472-8206.2010.00905.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

An HIV-infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption followed by very fast drug clearance probably attributable to his genetic background. This case underlines the importance of traditional and pharmacogenetic-based TDM for the individualization of ATV therapy in HIV-1 patients.

引用

页码：204 / 206

页数：3

共 13 条

[1]

[Anonymous], 2009, GUID US ANT AG HIV 1

[2] Clinical pharmacology, efficacy and safety of atazanavir: a review [J].

Bentue-Ferrer, Daniele ;

Arvieux, Cedric ;

Tribut, Olivier ;

Ruffault, Annick ;

Bellissant, Eric .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (11) :1455-1468

[3] Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection [J].

Cattaneo, Dario ;

Maggiolo, Franco ;

Ripamonti, Diego ;

Perico, Norberto .

JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2008, 46 (06) :485-489

[4] Atazanavir A Review of its Use in the Management of HIV-1 Infection [J].

Croom, Katherine F. ;

Dhillon, Sohita ;

Keam, Susan J. .

DRUGS, 2009, 69 (08) :1107-1140

[5]

Gianotti N, 2005, NEW MICROBIOL, V28, P119

[6] P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir [J].

Janneh, Omar ;

Anwar, Tariq ;

Jungbauer, Christof ;

Kopp, Stefan ;

Khoo, Saye H. ;

Back, David J. ;

Chiba, Peter .

ANTIVIRAL THERAPY, 2009, 14 (07) :965-974

[7] A "silent" polymorphism in the MDR1 gene changes substrate specificity [J].

Kimchi-Sarfaty, Chava ;

Oh, Jung Mi ;

Kim, In-Wha ;

Sauna, Zuben E. ;

Calcagno, Anna Maria ;

Ambudkar, Suresh V. ;

Gottesman, Michael M. .

SCIENCE, 2007, 315 (5811) :525-528

[8]

Lakhman SS, 2009, PHARMACOGENOMICS, V10, P1323, DOI [10.2217/pgs.09.53, 10.2217/PGS.09.53]

[9] Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir [J].

Le Tiec, C ;

Barrail, A ;

Goujard, U ;

Taburet, AM .

CLINICAL PHARMACOKINETICS, 2005, 44 (10) :1035-1050

[10] Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia [J].

Rodriguez-Novoa, Sonia ;

Martin-Carbonero, Luz ;

Barreiro, Pablo ;

Gonzalez-Pardo, Gema ;

Jimenez-Nacher, Inmaculada ;

Gonzalez-Lahoz, Juan ;

Soriano, Vincent .

AIDS, 2007, 21 (01) :41-46

← 1 2 →